More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

The conference’s abstract drop features ASC4First in its plenary session.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

The company makes no secret of the need for durability with its anti-CD47 project SL-172154.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.